Your Position: Home > Journal List > China Medicine > Paper

Gemcitabine combined with oxaliplatin in treatment of relapsed and refractory diffuse large B-cell lymphoma

( views:604, downloads:0 )
Author:
LIU Yong-zhong(Department of Chemotherapy,Zhongshan City People's Hospital,Guangdong Province,Zhongshan 528403,China)
LIANG Shu-yi()
LIN Gui-nan(Department of Chemotherapy,Zhongshan City People's Hospital,Guangdong Province,Zhongshan 528403,China)
PENG Jie-wen(Department of Chemotherapy,Zhongshan City People's Hospital,Guangdong Province,Zhongshan 528403,China)
YIN Zhao-feng(Department of Chemotherapy,Zhongshan City People's Hospital,Guangdong Province,Zhongshan 528403,China)
LIANG Han-lin(Department of Chemotherapy,Zhongshan City People's Hospital,Guangdong Province,Zhongshan 528403,China)
HE Jing-huan(Department of Chemotherapy,Zhongshan City People's Hospital,Guangdong Province,Zhongshan 528403,China)
Journal Title:
China Medicine
Issue:
Volume 07, Issue 11, 2012
DOI:
10.3760/cma.j.issn.1673-4777.2012.11.021
Key Word:
Diffuse large B-cell lymphoma;Chemotherapy;Gemcitabine;Oxaliplatin

Abstract: Objective To evaluate the short-term effect and side effects of GEMOX regimen in treating the patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL).Methods Twenty-seven patients with relapsed and refractory DLBCL were treated with GEMOX regimen,GEMOX regimen:gemcitabine (GEM)1000 mg/m2 IVD on day 1 and 8; oxaliplatin (L-OHP) 100 mg/m2 IVD on day 2; treatment was repeated every 3weeks with at least 2 cycles of chemotherapy for each patient.Results The response rate of relapsed group was 64.7% (11/17) ; the median time to progression (m-TTP) was 7.5 months (95% CI 6.8-8.2 months).The response rate of refractory group was 60.0% (6/10) and m-TTP was 6.2 months(95% CI 5.3-7.1 months).There were no differences between relapsed group and refractory group in the response rate,but there were differences in m-TTP.The main side effects included marrow suppression such as leucopenia and thrombocytopenia.No patients died of toxic reactions of chemotherapy.Conclusion GEMOX regimen is a safe and effective salvage regimen for the patients with relapsed and refractory DLBCL.

  • [1]周生余,石远凯,何小慧,等.DICE方案治疗复发或耐药中高度恶性非霍奇金淋巴瘤.癌症,2005,24(4):465-469.
  • [2]蔡清清,高岩,周颖,等.DHAOx方案治疗复发和难治性非霍奇金淋巴瘤的研究.中山大学学报:医学科学版,2010,31(2):269-273.
  • [3]Li ZW,Dalton WS.Tumor microenvironment and drug resistance in hematologic malignancies.Blood Rev,2006,20(6):333-342.
  • [4]Shapiro JD,Millward MJ,Rischin D,et al.Activity of gemcitabine in patients with advanced ovarian cancer:responses seen following platinum and paclitaxel.Gynecol Oncol,1996,63(1):89-93.
  • [5]张开芳,王森,白淑琴.吉西他滨联合顺铂治疗对蒽环类耐药的晚期乳腺癌30例临床分析.中国综合临床,2004,20(7):624-625.
  • [6]Foss(a) A,Santoro A,Hiddemann W,et al.Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma.J Clin Oncol,1999,17 (12):3786-3792.
  • [7]van Moorsel C J,Pinedo HM,Veerman G,et al.Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.Br J Cancer,1999,80 (7):981-990.
  • [8]Zinzani PL,Venturini F,Stefoni V,et al.Gemcitabine as single agent in pretreated T-cell lymphoma patients:evaluation of the long-term outcome.Ann Oncol,2010,21 (4):860-863.
  • [9]王学文,李锋.外周T细胞淋巴瘤的研究进展.现代肿瘤医学,2009,17(6):1173-1178.
  • [10]Oki Y,McLaughlin P,Pro B,et al.Phase Ⅱ study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma.Cancer,2005,104(4):781-787.
  • [11]Germann N,Brienza S,Rotarski M,et al.Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients.Ann Oneol,1999,10(3):351-354.
  • [12]谢春英,娄思源,王顺金,等.健择加国产草酸铂联合治疗晚期非小细胞肺癌的临床研究.实用癌症杂志,2003,18(3):297-298.
  • [13]文兆明,胡正清.吉西他滨联合奥沙利铂和地塞米松治疗复发或难治性非霍奇金淋巴瘤21例疗效观察,江西医药,2010,45(6):557-559.
  • [14]石远凯,于燕霞.非霍奇金淋巴瘤治疗进展.临床肿瘤学杂志,2006,11(7):481-485.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn